Stem Cell Club - Header Component
⏳ Standard price $2,499$1,999 locked in for life during our current promotion. Book now →
Advanced Regenerative Science

MUSE Cells:
The Next Generation
of Stem Cell Therapy

You've probably heard about stem cells. But inside the products most clinics use, there's a rare and powerful subpopulation that's beginning to redefine what regenerative medicine can do. They're called MUSE cells—and what makes them extraordinary also makes them easy to misunderstand.

🔬 Published clinical trials
🏥 FDA-registered lab sourcing
✅ Education-first approach
3
Germ layers MUSE cells can differentiate into
0
Known tumor risk in published safety data

~1–2%
Of MSCs in umbilical cord tissue are MUSE cells
2010
Discovered by Professor Mari Dezawa, Tohoku University
🧪 FDA-Registered Lab Partners
🏥 St. George, UT & Las Vegas, NV
🔬 Phase 2 Clinical Trial Data
📋 Education-First. Always.

What Does "MUSE" Actually Mean?

The name isn't just clever—each letter describes a property that sets these cells apart from every other stem cell type in clinical use today.

M
Multi-lineage Differentiating
MUSE cells can differentiate into all three germ layers—ectoderm, mesoderm, and endoderm. In practical terms, they may become nerve cells, heart cells, liver cells, muscle cells, and more. This tri-lineage capability is a property previously only seen in embryonic or induced pluripotent stem cells—which carry significant tumor risks that MUSE cells do not.
S
Stress-Enduring
MUSE cells were actually discovered by accident—Professor Dezawa left an enzyme in a petri dish overnight, killing nearly every cell in the culture. One cell survived. That survival-against-the-odds is built into MUSE biology. Injured tissue is a harsh, inflamed, oxygen-deprived environment. Most transplanted cells die within hours. MUSE cells are uniquely equipped to survive—and function—in exactly that environment.
E
Cells
A naturally occurring subpopulation found within mesenchymal stem cell (MSC) populations. They are not engineered or genetically modified—they already exist inside umbilical cord tissue, bone marrow, and adipose tissue in small numbers, typically representing about 1–2% of MSCs in any given sample.
💡

Why You Haven't Heard More About MUSE Cells

MUSE cells were discovered the same year that Professor Shinya Yamanaka received worldwide attention for induced pluripotent stem cells (iPSCs)—work that eventually earned a Nobel Prize. Professor Dezawa's discovery was quietly published in the same year and largely overshadowed. Today, MUSE cells are generating significant scientific interest because they may offer many of the same pluripotent advantages without the tumor risk that has slowed iPSC clinical translation.

Four Capabilities That Set MUSE Cells Apart

Standard MSCs are broadly useful and well-studied. MUSE cells sit within that same family—but bring specific biological properties that distinguish them in both lab research and early clinical trials.

🧭

Active Homing to Injury Sites

MUSE cells express a receptor called S1PR2 that allows them to chemically "sense" damage signals and navigate toward them after an IV infusion. Published Phase 2 clinical trials have documented MUSE cells traveling to the brain (stroke), heart (heart attack), and other target tissues without direct injection. This homing behavior is a property standard MSCs do not reliably demonstrate.

🔄

True Tri-Lineage Differentiation

Most stem cells used in clinics today work primarily through paracrine signaling—releasing growth factors and anti-inflammatory molecules. MUSE cells appear capable of actual tissue integration: engrafting into damaged areas, consuming damaged cell fragments through a process called phagocytosis, and potentially regenerating functionally younger replacement cells. This has been observed in cardiac, neurological, and orthopedic preclinical models.

🛡️

Immune Privilege — No Immunosuppressants Required

One of the most practical advantages in a clinical setting: MUSE cells express very low levels of HLA antigens, meaning the immune system does not recognize them as foreign. Published Phase 2 safety data has confirmed that patients can receive allogeneic (donor) MUSE cells without immunosuppressant medications and without rejection events. No comparable data exists for isolated standard MSCs at scale.

Non-Tumorigenic Pluripotency

The clinical barrier to using more powerful pluripotent stem cells—like iPSCs or embryonic stem cells—has always been tumor risk. MUSE cells express pluripotency markers (OCT4, SOX2, NANOG) associated with broad differentiation capability but do not express the c-Myc marker linked to uncontrolled cell proliferation and teratoma formation. This is the defining safety advantage that makes MUSE cells a realistic clinical candidate where iPSCs are not.

Property Standard MSCs MUSE Cells
Tumor risk Low — no teratoma, but limited differentiation ✓ Non-tumorigenic pluripotency
Differentiation capability Primarily mesoderm lineage ✓ All three germ layers
Homing to injury Inconsistent, passive ✓ Active via S1PR2 receptor
Tissue engraftment Rare; primarily paracrine effect ✓ Documented in clinical trials
Immune rejection risk Moderate; phagocytized over time ✓ Low HLA expression; no immunosuppressants needed
Survival in hostile environments 95%+ may die within 24 hrs post-injection ✓ Stress-enduring by definition
Clinical trial data Extensive across many conditions ✓ Phase 2 data: stroke, MI, ALS, neonatal brain injury

MUSE Cells Are Powerful.
But They Are Not Meant to Work Alone.

This is the part most clinics and most marketing won't tell you—because it complicates the sales pitch. But it's the part we think matters most.

🦾

MUSE Cells

The specialists. Pluripotent differentiation, injury homing, tissue integration.

🧠

Conventional MSCs

The managers. Broad immune modulation, paracrine signaling, inflammation control.

🔧

Stromal & Perivascular Cells

The support staff. Structural scaffolding, vascular support, microenvironment balance.

🏗️

Extracellular Matrix

The building and tools. Context-dependent signaling that tells cells how to behave.

You don't run a hospital with surgeons alone. The body heals through coordinated cellular teamwork—and any therapy that isolates a single cell type removes that balance.

What Happens When Cells Are Isolated and Given Alone

This applies to isolated MSCs and isolated MUSE cells alike. Nature designed cellular cooperation.

Increased inflammation risk. Companion MSC populations buffer T-cell activation and macrophage polarization. Without them, cytokine release can be amplified rather than suppressed.

Microvascular trapping. Isolated cells may lodge in pulmonary or hepatic microvasculature. Stromal and perivascular companions normally mitigate this risk.

Dysregulated differentiation. Without contextual ECM and paracrine signals, cellular behavior becomes unpredictable—differentiation may be incomplete or maladaptive.

Higher outcome variability. Single-cell-type products show significantly greater batch-to-batch and patient-to-patient variability than preserved cellular ecosystems.

This is why the most biologically coherent therapies preserve the native cellular ecosystem—especially from developmentally young tissues like Wharton's Jelly umbilical cord.

What Are MUSE Cell Exosomes—And Why Do They Matter?

Exosomes are tiny signaling particles released by cells. Think of them as biological text messages: packets of microRNA, proteins, and lipids that carry instructions telling nearby tissue how to repair, regulate, or regenerate.

If cells are the workers, exosomes are the messages they send.

MUSE-derived exosomes are particularly interesting because they originate from cells that are defined by surviving stress. The signals they carry reflect that biology: research has found MUSE cell secretions to be enriched with factors involved in stemness regulation, apoptosis control, immune modulation, oxidative stress balance, and extracellular matrix remodeling.

In practical terms: if you're trying to send regenerative signals into an inflamed, oxidatively stressed tissue environment, you want those signals coming from a cell type built for that exact environment.

MSC Exosomes vs. MUSE Exosomes

Standard
MSC Exosomes
Broader evidence base. Well-studied across many condition models. Heterogeneous signaling profile. Reliable general-purpose anti-inflammatory and regenerative effects. A trusted foundation for exosome therapy.

MUSE exosome research is early-stage. We present this honestly—promising mechanistically, not yet proven at clinical scale. That's a meaningful distinction.

Straight Answers About MUSE Cells

Are MUSE cells the same as MSCs?
No—but they're related. MUSE cells are a rare subpopulation found within MSC populations, typically representing about 1–2% of MSCs in umbilical cord tissue. They share the MSC family but have distinct biological capabilities that standard MSCs don't possess: tri-lineage differentiation, active injury homing, superior stress survival, and documented tissue engraftment in clinical settings.
Is there real clinical trial data on MUSE cells?
Yes. Published Phase 2 trials include: ischemic stroke (systemic IV, significant ADL improvement in 100% of subjects), acute myocardial infarction (left ventricular ejection fraction improved from 40% to 52% with a single IV infusion), ALS (monthly infusions showed stabilization signals in a Phase 1 study), and neonatal hypoxic-ischemic encephalopathy. These are small trials—larger Phase 3 studies are in planning—but the safety profile has been consistently favorable, with no serious adverse events and no need for immunosuppression reported across published data.
Why don't MUSE cells cause tumors if they're pluripotent?
The tumorigenicity of embryonic stem cells and iPSCs is linked to c-Myc, a transcription factor involved in uncontrolled cell proliferation. MUSE cells express the other pluripotency markers (OCT4, SOX2, NANOG) but not c-Myc at dangerous levels. Additionally, MUSE cells are stress-enduring rather than rapidly proliferating—they respond to contextual signals from damaged tissue rather than growing uncontrollably. Published safety data across multiple Phase 2 trials has not identified tumor formation in any subject.
Do the products at The Stem Cell Club contain MUSE cells?
Our standard APEX™ Wharton's Jelly MSC products naturally contain MUSE cells as part of the preserved cellular population—consistent with the ~1–2% presence in cord tissue. We also offer a MUSE Cell Combo add-on protocol for patients who want an enhanced MUSE-specific component added to their treatment plan. Speak with our clinical team to understand which protocol may be appropriate for your situation.
How is MUSE cell therapy administered—is it an injection or an IV?
The published clinical trial data on MUSE cells predominantly uses systemic IV infusion—and that's one of the remarkable findings. Because MUSE cells actively home to injury sites via S1PR2 receptor signaling, patients in stroke and cardiac trials received simple IV drips without direct organ injection, and the cells navigated to the target tissue on their own. At The Stem Cell Club, we offer both IV and injection protocols depending on the condition being addressed. Your APRN will help determine which approach is most appropriate.
Is MUSE cell therapy FDA-approved?
No regenerative stem cell therapy involving allogeneic MSC or MUSE products is FDA-approved as of this writing. These therapies are offered under the FDA's framework for same-day procedures using minimally manipulated, homologously used cell products. Phase 3 trials are in planning for acute MI, which may eventually lead to an approved indication. We are transparent about this distinction—and about what the current evidence does and does not support. Our protocols use only FDA-registered lab partners.
What conditions may benefit from MUSE cell therapy?
Clinical trial and real-world use data suggests potential benefit in: joint and orthopedic conditions (knee, hip, shoulder, spine), neurological conditions (stroke recovery, ALS, Alzheimer's research), cardiovascular recovery (post-heart attack), chronic inflammatory conditions, autoimmune conditions, and longevity/anti-aging protocols. We tailor every recommendation to the individual—and we're honest when we believe stem cell therapy is unlikely to help a given situation.

It's Not About More Cells.
It's About the Right Cells, Working Together.

If you're curious about how regenerative medicine is evolving—or want an honest opinion on whether it makes sense for you—reach out. We educate first and guide second. Always.

FTC Disclaimer & Important Notice: The information on this page is educational in nature and does not constitute medical advice. Stem cell therapy, including MUSE cell therapy, is not FDA-approved for the treatment of any condition listed herein. Individual results vary and cannot be guaranteed. Published clinical trial data cited is preliminary; larger randomized controlled trials are ongoing. The Stem Cell Club does not claim to diagnose, treat, cure, or prevent any disease. Consult with a licensed medical professional before beginning any new treatment. References to third-party research are for educational context only and do not imply endorsement.